Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H5N1 - Seqirus

Drug Profile

Influenza A virus vaccine H5N1 - Seqirus

Alternative Names: Aflunov; aH5N1c; AUDENZ; FCC H5N1; Flu Cell Culture H5N1; Influenza A (H5N1) Monovalent Vaccine, Adjuvanted - Seqirus; Influenza A virus strain H5N1 vaccine - Seqirus; MF59®-Adjuvanted Pandemic Influenza Vaccine - Seqirus; MF59®-adjuvanted-H5N1 subunit vaccine; Pre-pandemic H5N1 influenza vaccine - Seqirus; Pre-pandemic influenza vaccine - Seqirus

Latest Information Update: 05 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Novartis Vaccines
  • Developer Seqirus
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 03 Feb 2020 Registered for Influenza A virus H5N1 subtype (Prevention, In infants, In children, In adolescents, In adults, In the elderly) in USA (IM)
  • 30 Aug 2019 The US FDA accepts sBLA for influenza A virus vaccine H5N1 in Influenza A virus H5N1 subtype (Prevention)
  • 30 Aug 2019 Immunogenicity data from three phase II trials in Influenza A virus H5N1 subtype released by Seqirus
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top